EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

CD28-ICOS costimulation enhances the therapeutic efficacy of L1CAM-targeted CAR-T cells against ovarian and gastric cancers

Xiumei Che, Un-Jung Yun, Junsub Lee, Hyun-Hee Koh, Ju-Yeon Lee, Jungmin Jeon, Subin So, Youngyoub Kim, Jin-A Chae, Xianglan Zhang, Hyoyoung Kim, Jiwoo Hwang und 4 weitere

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2025-014131 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Xiumei Che und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea (the Republic of). Hauptthemen laut MEDLINE: Stomach Neoplasms, Ovarian Neoplasms, Neural Cell Adhesion Molecule L1, Immunotherapy, Adoptive. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Korea Drug Development Fund, Korea Health Industry Development Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ovarian and gastric cancers are associated with poor prognosis and derive limited benefit from current therapies, highlighting the need for novel immunotherapeutic approaches. The L1 cell adhesion molecule (L1CAM) is aberrantly expressed in several types of solid tumors and is associated with aggressive clinical behavior. This study aimed to develop and characterize optimized L1CAM-targeted chimeric antigen receptor-T (CAR-T) cells with improved efficacy and safety, using patient-derived preclinical models of ovarian and gastric cancer.

Methods

L1CAM expression was assessed in tumor tissues from patients with ovarian cancer (OC;n=227) and gastric cancer (GC;n=132), followed by an analysis of its clinical impact. A panel of L1CAM-targeted CAR constructs incorporating distinct hinge and co-stimulatory domains was systematically evaluated. Functional activity was assessed by cytotoxicity and cytokine release assays using cancer cell lines and patient-derived tumor cells. Antitumor efficacy, persistence, and safety were evaluated in xenograft and patient-derived xenograft (PDX) models, including NanoLuc-based in vivo tracking of CAR-T cell distribution.

Results

High L1CAM expression correlated with aggressive clinicopathological features and adverse prognosis in patients with OC. Among the constructs tested, CAR-T cells incorporating an IgD/IgG1 hybrid hinge and dual CD28-ICOS co-stimulatory domains demonstrated the most potent antigen-specific activity. These cells exhibited enhanced cytotoxicity, robust interferon-γ production, and sustained functional activity. In vivo, optimized L1CAM CAR-T cells achieved complete tumor regression in OC PDX models and significant tumor suppression in GC models, with durable tumor control and CAR-T persistence. Intraperitoneal delivery further improved therapeutic efficacy and CAR-T cell localization compared with intravenous administration. Importantly, no evidence of neurotoxicity or systemic toxicity was observed, supporting a favorable safety profile.

Conclusions

Optimized L1CAM-targeted CAR-T cells demonstrate potent, durable, and antigen-specific antitumor activity with a favorable safety profile in preclinical models of OC and GC. The combination of rational CAR design (CD28-ICOS signaling) and optimized delivery strategy provides a strong rationale for the clinical development of L1CAM-targeted CAR-T therapy, particularly in patients with L1CAM-positive solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsOvarian NeoplasmsNeural Cell Adhesion Molecule L1Immunotherapy, AdoptiveCD28 AntigensReceptors, Chimeric AntigenHumansFemaleAnimalsMiceXenograft Model Antitumor AssaysCell Line, TumorMiddle Aged

Stichwörter der Autor:innen

Adoptive cell therapy - ACTGastric CancerImmunotherapyOvarian Cancer

Substanzen

Neural Cell Adhesion Molecule L1CD28 AntigensL1CAM protein, humanReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea (the Republic of).
  • Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea (the Republic of).
  • Research & Development Department, Helixmith Co Ltd, Seoul, Korea (the Republic of).
  • Department of Pathology, Yonsei University College of Medicine, Seoul, Korea (the Republic of).
  • Department of Pathology, Yanbian University Hospital, Yanji, Jilin, China.
  • Oral Cancer Research Institute, Yonsei University College of Dentistry, Seoul, Korea (the Republic of).

Förderung

  • National Research Foundation of Korea
  • Korea Drug Development Fund
  • Korea Health Industry Development Institute

Zitieren

APA

Che, X., Yun, U. J., Lee, J., Koh, H. H., Lee, J. Y., Jeon, J., So, S., Kim, Y., Chae, J. A., Zhang, X., Kim, H., Hwang, J., Park, E., Nam, E. J., Kim, G. M., & Jung, M. (2026). CD28-ICOS costimulation enhances the therapeutic efficacy of L1CAM-targeted CAR-T cells against ovarian and gastric cancers. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-014131

Vancouver

Che X, Yun UJ, Lee J, Koh HH, Lee JY, Jeon J, et al. CD28-ICOS costimulation enhances the therapeutic efficacy of L1CAM-targeted CAR-T cells against ovarian and gastric cancers. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-014131

BibTeX
@article{Che2026,
  author = {Che, Xiumei and Yun, Un-Jung and Lee, Junsub and Koh, Hyun-Hee and Lee, Ju-Yeon and Jeon, Jungmin and So, Subin and Kim, Youngyoub and Chae, Jin-A and Zhang, Xianglan and Kim, Hyoyoung and Hwang, Jiwoo and Park, Eunhyang and Nam, Eun Ji and Kim, Gun Min and Jung, Minkyu},
  title = {CD28-ICOS costimulation enhances the therapeutic efficacy of L1CAM-targeted CAR-T cells against ovarian and gastric cancers},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2025-014131}
}
Kostenlos starten →